SBIR/STTR Research Award
Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping
Award amount
$529,787Program and phase
SBIR · Phase IAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- EPICYPHER, INC.
- Proposal award date
- 2022-02-01
- Contract end date
- 2023-01-31
- UEI
- UWNWSADJYYZ3
- Solicitation number
- PA21-071
- Topic code
- NHGRI
Research abstract
Candidate Eligibility StatementThe goal of this diversity supplement application is to provide career development support for Dr. Allison
Hickman, a bioinformatician who aspires to (and with support could perform) leadership roles in commercial
science. Women have been under-represented in science leadership, particularly in the field of bioinformatics,
and this award would formally address the issue by supporting a truly talented individual. Dr. Hickman is a US
citizen and full-time employee at EpiCypher Inc., a Small Business Concern (SBC) eligible to submit applications
to the National Institutes of Health. EpiCypher was recently awarded an SBIR Fast-Track Grant from NHGRI
[R44 HG011875] that is currently in year one (of three) and is eligible for diversity supplement support.
5.12.2022
Dr. Allison Hickman - Diversity Supplement Candidate (Research Scientist) Date
5.11.2022
Dr. Martis Cowles - EpiCypher Signing Official (Chief Business Officer) Date
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development of novel epigenetic biomarkers and detection reagents for aging
- Epigenomic analysis of cell-free nucleosomes for cancer research
- Asymmetric nucleosome substrates to advance the study of the histone code
- Versatile genomics platform for unbiased analysis of chromatin-associated RNAs and nascent transcripts
- Scalable and quantitative chromatin profiling from formalin-fixed paraffin-embedded samples
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Platform to support clinical variant interpretation through probabilistic assessment of functional evidence
- Innovations to expand and accelerate the commercial impact of DNA modifications
- High-throughput Direct Sequencing and Quantitative Mapping of RNA Modifications using Mass Spectrometry.
- Super-resolution single-molecule sequencing by observing the dynamic hybridization of a repertoire of oligonucleotides to DNA targets
- Exhaustive de novo sequencing of every RNA in a sample by a layer-by-layer mass spectrometry ladder intensity approach.
Research funding history
64 SBIR/STTR records share this UEI (2014–2025). Reported award amounts total $79,150,531. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services